For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® h 232 POC system
On the spot results to support efficient diagnosis and management of cardiovascular diseases
IVD
For in vitro diagnostic use.
On-the-spot care and share
The cobas h 232 POC system is a portable point-of-care system to support optimized diagnostics and treatment of patients with cardiovascular disease. Designed for healthcare providers, it delivers objective results that are aligned with the Roche laboratory methods and can be shared wirelessly for immediate feedback and response.
Fast
On-the-spot results are available in 12 minutes or less1,2,3,4,5
Portable
Handheld point of care system is lightweight and easy to use, even in mobile situation6
Confident
Accurate results, aligned with Roche central laboratory tests7
Governance
Connection to the cobas® infinity POC solution helps remote management of the POC testing and quality assurance from a single location.6
Available tests
View Full TableAvailable tests
The cobas h 232 POC system allows rapid and easy determination of Troponin T, NT-proBNP, D-Dimer, CK-MB and Myoglobin in different settings, like ambulances, general practitioner offices and emergency rooms.
The cobas h 232 POC system allows rapid and easy determination of Troponin T, NT-proBNP, D-Dimer, CK-MB and Myoglobin in different settings, like ambulances, general practitioner offices and emergency rooms.
| Test | Measuring range | Time to result | Clinical utility |
|---|---|---|---|
| Troponin T | 40 – 2,000 ng/L |
12 min |
Early aid in diagnosis of acute myocardial infarction and identification of patients with an elevated mortality risk1 |
| NT‑proBNP | 60 – 9,000 pg/mL |
12 min |
Aid in diagnosis of patients with suspected heart failure, in monitoring of patients with compensated left ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes2 Help in the CV risk assessment of patients with T2D. Aid in the identification of patients at CV risk with T2D without known history of CV disease to optimize cardioprotective treatment Can be used to identify elderly individuals at high‐risk for atrial fibrillation2 |
| D-Dimer | 0.1 - 4.0 µg/mL | 8 min | Aid in exclusion of deep venous thrombosis and pulmonary embolism3 |
| CK-MB | 1.0 – 40 ng/mL | 12 min | Aid in diagnosis of patients with suspected AMI, assessment of the size of the infarction and detection of re-infarction4 |
| Myoglobin | 30 – 700 ng/mL |
8 min | Aid in diagnosis of patients with suspected myocardial infarction, reperfusion control5 |
AMI: Acute Myocardial Infarction; NT-proBNP: N-terminal pro b-type natriuretic peptides; POC: Point of Care; CV: Cardiovascular; T2D: Type 2 diabetes
Management of heart failure (HF) in the primary care settings
NT-proBNP helps to early detect Type 2 Diabetes (T2D) patients at high risk of HF, regardless of previous history of cardiovascular disease.8
- Type 2 Diabetes patients are at increased risk of cardiovascular disease.8
- NT-proBNP value > 125 pg/mL helps identify T2D patients in need of intensified care and improve HF outcomes.8,9
- NT-proBNP POC testing is practical and can be pragmatically targeted for screening people with T2D in routine clinical practice.10
NT-proBNP on cobas h 232 supports the initial diagnosis of HF and the monitoring of the disease progression in out-patient settings.2,11,12
The story of Paul and the management of his chronic heart failure
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
NT-proBNP testing on the cobas h 232 POC system supports rapid up-titration as shown in the STRONG-HF study13
- Patients admitted for acute HF can be rapidly and safely up-titrated to recommended doses of guideline-directed medical therapy by following the strategy that includes NT-proBNP.
- HCPs, patients and their families can benefit from an improvement in post-discharge management leading to reductions of the re-hospitalization and mortality and enhanced patient quality of life.
Enabling faster triaging decisions for patients with suspected acute myocardial infarction in pre-hospital setting and emergency room
Pre-hospital measurement of POC Troponin T allows early identification of patients at high risk of mortality and helps ensure a fast triage to the correct location.14, 15
Pre-hospital measurement of POC Troponin T in low-risk suspected NSTE-ACS patients can help save healthcare costs by reducing emergency department visits.16
POC Troponin T: Roche Cardiac POC Troponin T on cobas h 232, NSTE-ACS: non-ST-segment elevation acute coronary syndrome
References
- Roche Cardiac POC Troponin T Method Sheet V 3.0 (2019).
- Roche Cardiac NT-proBNP Method Sheet V 2.0 (2024).
- Roche Cardiac D-Dimer Method Sheet V 6.0 (2023).
- Roche Cardiac CK-MB Method Sheet V 5.0 (2018).
- Roche Cardiac M Method Sheet V 7.0 (2018).
- Roche cobas h 232 POC system Operator's Manual V 7.0 (2022).
- Bertsch T et al. (2010). Clin Lab 56(1-2): 37-49.
- Huelsmann M et al. (2008). Eur Heart J 29(18): 2259-2264.
- Huelsmann M et al. (2013). J Am Coll Cardiol 62(15): 1365-1372.
- Ceriello A et al. (2023). J Diabetes Complications 37(3):108410.
- McDonagh TA et al. (2021). Eur Heart J 42(36): 3599-3726.
- Taylor CJ et al. (2017). Br J Gen Pract 67(660): 326-327.
- Mebazaa A et al. (2022). Lancet 400(10367): 1938-1952.
- Stengaard C et al. (2013). Am J Cardil 112(9): 1361-1366.
- Rasmussen MB et al. (2017). Eur Heart J 39(1): 5-6.
- Camaro J et al. (2023). Eur Heart J 44(19):1705-1714.
Use left and right arrow keys to scroll between the tabs
Overview
Technical Documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
